Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the audio recording of the earnings call held today i.e. Wednesday, May 22, 2024 at 09:00 a.m. (IST) to discuss the financials results of Q4 FY24 is available on the Company's website under the below link: https://www.metropolisindia.com/newdata/Investors/Financials/24-25/Q1/Metropolis-Q4FY24-Earnings-Call- Audio.mp3
22-05-2024
Bigul

Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Newspaper Advertisement of Audited Financial Results for the quarter and financial year ended March 31, 2024 published in Free Press Journal and Navshakti.
22-05-2024
Bigul

Q4FY24 Quarterly & FY24 Annual Result Announced for Metropolis Healthcare Ltd.

 Healthcare Services company Metropolis Healthcare announced Q4FY24 & FY24 results: Core Business Revenue increased by 15% for Q4FY24 & 13% for FY24 on YoY basis Core Business patient volume stood at 2.98 million for Q4FY24 and 11.59 million for FY24 with a growth of 7% & 9% respectively on YoY basis B2C Revenue grew by 20% for Q4FY24 YoY TruHealth Wellness & Specialized segment revenues grew by 22% & 17% respectively for Q4FY24 on YoY basis Reported EBITDA stood at 25.5% for Q4FY24. EBITDA before CSR & ESOP stood at 26.4%. Contribution of premium wellness stood at 15% in Q4FY24. B2C revenue growth in Mumbai at 20% in Q4FY24 YoY. Ameera Shah, Managing Director, Metropolis Healthcare, said, “We have consistently surpassed industry volume growth for the past eight quarters and remain optimistic about continuing this trend. Despite significant network expansion over the last two years, we achieved EBITDA margins of 25.5% in Q4 FY24. Looking ahead, we expect additional revenue from both existing and new networks, coupled with improved operational efficiency, to sustain our current margin levels in FY25 and further enhance our margin profile beyond FY25. Over the past many years, we have been focusing on professionalizing the company and have been adding talent to our senior management team. With Surendran & the team of CXO’s, in place and delivering results, I am more confident of achieving greater heights. We believe this is an appropriate time for me to hand over the baton to Surendran & team to execute our strategies, while I will move to the position of Executive Chairperson & Whole Time Director with steady focus on driving the strategy, strengthening governance, strategizing capital allocation, acquiring talent and foster the culture at Metropolis. As we progress with our Metropolis 3.0 strategy, along with organic growth via existing network and expansion. M&A; will be pivotal in elevating our position. Our goal is to enhance our technical testing capabilities and enter new markets, bolstering our strengths and ensuring sustainable growth.” Surendran Chemmenkotil, CEO, Metropolis Healthcare, said, "As we reflect on our Q4 performance, I am delighted to share our remarkable achievements, in Q4FY24, our core business revenues grew by 15% year-on-year, with volume growth of 7%+. Our B2C revenues grew by ~20% y-o-y, additionally, our revenues from Mumbai market witnessed an impressive growth of 20%, highlighting our brand strength. Looking ahead, we are confident in scaling up revenue in the coming quarters, showcasing a promising trend of positive operating leverage. Guided by our strategic vision, we have diligently focused on expanding our network, driving volume and revenue growth, and optimizing efficiency, productivity, and margins. We have expanded our footprint significantly, from around 300 towns in FY23 to surpassing 600 towns by FY24, with intentions to extend our coverage nationwide. We are reinforcing our strategy of expanding our footprints venturing into Tier 3 and Tier 4 towns, while also concentrating efforts in vital clusters across our core geographies Going forward with brand strength of metropolis, talent pool, trusted partners for doctors and consumers coupled with aggressive expansion plans, foray into adjacencies with opportunities of inorganic growth, we are optimistic of outnumbering in the industry growth in terms of revenue growth and profitability." Result PDF
22-05-2024

Metropolis Healthcare Results Earnings Call for Q4FY24

 Conference Call with Metropolis Healthcare Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.
22-05-2024

Metropolis Healthcare Q4 Results: Profit Up 9%, Meets Estimates

 The company posted a profit of Rs 37 crore in the quarter-ended March, in comparison with Rs 33 crore in the year-ago period.
21-05-2024
Bigul

Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Investor Presentation for the quarter ended March 31, 2024.
21-05-2024
Bigul

Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press Release
21-05-2024
Bigul

Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Outcome of Board Meeting
21-05-2024
Bigul

Metropolis Healthcare Ltd - 542650 - Board Meeting Outcome for The Meeting Held Today I.E., May 21, 2024

 Outcome of Board Meeting
21-05-2024
Bigul

Metropolis Healthcare Ltd - 542650 - Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2024

 Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2024
21-05-2024
Next Page
Close

Let's Open Free Demat Account